REG - BioPharma Credit PLC - Appointment of Joint Corporate Broker

Biopharma CreditAnnouncement

20/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250320:nRST3833Ba&default-theme=true

RNS Number : 3833B  BioPharma Credit PLC  20 March 2025

20 March 2025

 

BioPharma Credit plc

 

(the "Company")

 

APPOINTMENT OF JOINT CORPORATE BROKER

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
is pleased to announce the appointment of Investec Bank plc as joint corporate
broker to work alongside JPMorgan Cazenove, the Company's existing corporate
broker, with effect from 10 March 2025.

 

The contact information for the Company's joint corporate brokers is as
follows:

 

 JPMorgan Cazenove                                       Investec Bank plc
 William Simmonds william.simmonds@jpmorgancazenove.com  David Yovichic

                                                         david.yovichic@investec.com
 Mary-Jane Clarke                                        Lucy Lewis

 mary-jane.clarke@jpmorgan.com                           lucy.lewis@investec.com

 

 

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPGZGMFGLVGKZZ